A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

Published:2013-02-25 Issue:3 Volume:161 Page:357-366
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Voorhees Peter M.¹,Manges Robert F.²,Sonneveld Pieter³,Jagannath Sundar⁴,Somlo George⁵,Krishnan Amrita⁵,Lentzsch Suzanne⁶,Frank Richard C.⁷,Zweegman Sonja⁸,Wijermans Pierre W.⁹,Orlowski Robert Z.¹⁰,Kranenburg Britte¹¹,Hall Brett¹²,Casneuf Tineke¹³,Qin Xiang¹²,van de Velde Helgi¹³,Xie Hong¹²,Thomas Sheeba K.¹⁰

Affiliation:

1. Division of Hematology-Oncology; University of North Carolina Lineberger Comprehensive Cancer Center; Chapel Hill; NC; USA

2. Investigative Clinical Research of Indiana; LLC; Indianapolis; IN; USA

3. Department of Haematology; Erasmus Medical Centre and University; Rotterdam; The Netherlands

4. Division of Hematology and Medical Oncology; Mount Sinai Medical Center; New York; NY; USA

5. Department of Hematology and Hematopoietic Cell Transplantation; City of Hope Medical Center; Duarte; CA; USA

6. Division of Hematology-Oncology; University of Pittsburg School of Medicine and Cancer Institute; Pittsburg; PA; USA

7. Oncology Division; Whittingham Cancer Center at Norwalk Hospital; Norwalk; CT; USA

8. Department of Haematology; Vrije Universiteit Medical Centre; Amsterdam; The Netherlands

9. Department of Haematology; Haga Hospital; the Hague; The Netherlands

10. Department of Lymphoma/Myeloma; The University of Texas M. D. Anderson Cancer Center; Houston; TX; USA

11. Janssen Biologics Europe; Leiden; The Netherlands

12. Janssen Research & Development; Spring House; PA; USA

13. Janssen Research & Development; Beerse; Belgium

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12266/fullpdf

Reference35 articles.

1. Response patterns of purified myeloma cells to hematopoietic growth factors;Anderson;Blood,1989

2. Clinically relevant end points and new drug approvals for myeloma;Anderson;Leukemia,2008

3. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant;Blade;British Journal of Haematology,1998

4. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism;Chauhan;Oncogene,1997

5. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro;Cheung;Leukemia,2001

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting inflammation as cancer therapy;Journal of Hematology & Oncology;2024-03-22

2. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery;Journal of Experimental & Clinical Cancer Research;2024-01-20

3. Optimizing high dose melphalan;Blood Reviews;2023-12

4. Therapeutic potential of single-nucleotide polymorphism-mediated interleukin-6 receptor blockade in cancer treatment: A Mendelian randomization study;Heliyon;2023-10

5. Immune-epigenetic crosstalk in haematological malignancies;Frontiers in Cell and Developmental Biology;2023-09-21